Fresenius Medical Care

EQS-News: neurocare group AG Welcomes Norman Erhard as Senior VP Europe & Latin America

Retrieved on: 
Wednesday, April 10, 2024
Senior, Mental health, Growth, AG, Global leadership, Fresenius Medical Care, Management

April 2024 - neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice is pleased to announce the appointment of Norman Erhard as Senior Vice President Europe & Latin America, bolstering neurocare's Global Leadership.

Key Points: 
  • April 2024 - neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice is pleased to announce the appointment of Norman Erhard as Senior Vice President Europe & Latin America, bolstering neurocare's Global Leadership.
  • Norman Erhard brings with him a distinguished career spanning over three decades in the medical devices and clinic networks sector.
  • Norman's strategic acumen extends beyond corporate realms; he is an early investor in neurocare, reflecting his commitment to advancing healthcare innovation.
  • "We are thrilled to welcome Norman to the neurocare team," said Thomas Mechtersheimer, CEO of neurocare group AG.

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Retrieved on: 
Friday, March 22, 2024
Inclusion, Fresenius Medical Care, Letter, Science Based Targets initiative, Kidney, Patient, UN Women, Climate, Diversity, Science, Woman, Patient satisfaction, Annual report, The Annual Report, Dialysis, FME, BAD, German, Paris Agreement

Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.

Key Points: 
  • Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.
  • Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said: "The year 2023 was a transformative one for Fresenius Medical Care, as we set out to achieve important structural, operational, and cultural changes.
  • The 2023 Annual Report summarizes Fresenius Medical Care's steps to successfully deliver on the transformation and contains Fresenius Medical Care's Non-financial Group Report, providing a comprehensive overview of its progress of sustainability activities and achievements in three strategic focus areas:
    Enhancing quality care and access to health care: In about 4,000 dialysis clinics in around 50 countries worldwide, Fresenius Medical Care provided care for over 332,000 patients in 2023.
  • It is available for download as pdf-file on the company's website: Annual reports | Fresenius Medical Care .

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Retrieved on: 
Tuesday, March 19, 2024
Ready4, Fresenius Medical Care, Learning, Safety, Kidney, Augmented reality, Education, Knowledge, Hospital, Emergency medicine, Augment, Intensive care medicine, Dialysis, FME, BAD, ICU, Nursing, Health, Medtech

The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.

Key Points: 
  • The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.
  • Our innovative solution is designed to ensure that nursing staff, particularly those in Intensive Care Units, are equipped with the knowledge needed to provide high-quality and exceptional patient care," says Dr. Katarzyna Mazur-Hofsäß, member of the Management Board of Fresenius Medical Care AG and responsible for Care Enablement, Fresenius Medical Care's MedTech segment.
  • The AR glasses provide access to the Augmented Reality learning program Ready4 multiFiltratePRO AR, which Fresenius Medical Care presented today at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.
  • Ready4 multiFiltratePRO AR has been specifically developed for use with the multiFiltratePRO, Fresenius Medical Care's Continuous Kidney Replacement Therapy system.

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

Retrieved on: 
Wednesday, March 13, 2024
CEPSA, Fresenius Medical Care, Growth, Supervisory board, Labour, Risk, Kidney, General counsel, Knowledge, University, Doctor of Philosophy, Corporate governance, BAD, Human resources, Economics, Management

Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

Key Points: 
  • Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.
  • Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care AG, said: "We are delighted to welcome Jörg Häring to the Management Board of Fresenius Medical Care.
  • With his international experience and expertise in corporate governance and legal matters, he perfectly adds to the existing Management Board team.
  • Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said: "Jörg joins Fresenius Medical Care with more than two decades of career experience as a senior legal executive and corporate leader in the energy and healthcare sectors.

DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador

Retrieved on: 
Tuesday, March 5, 2024
Dialysis, Kidney disease, Patient, Caregiver, DaVita Inc., Fresenius Medical Care, IA Financial Group, Nursing

DENVER, March 5, 2024 /PRNewswire/ -- DaVita Inc (NYSE: DVA), a leading provider of kidney care services, today announced that it has agreed to terms on the expansion of its international operations in Brazil and Colombia, and its entry into Chile and Ecuador. The deal, which is consistent with DaVita's disciplined investment strategy, involves four separate acquisitions from Fresenius Medical Care for a total purchase price of $300M USD. The transaction in Chile closed effective today. The transactions in Ecuador, Colombia and Brazil remain subject to each country's respective anti-trust and regulatory approval processes, which are each expected to be completed at various times during 2024.

Key Points: 
  • The deal, which is consistent with DaVita's disciplined investment strategy, involves four separate acquisitions from Fresenius Medical Care for a total purchase price of $300M USD.
  • The transaction in Chile closed effective today.
  • The transactions in Ecuador, Colombia and Brazil remain subject to each country's respective anti-trust and regulatory approval processes, which are each expected to be completed at various times during 2024.
  • We look forward to building on our existing market expertise and the established quality of these centers through this transition."

DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador

Retrieved on: 
Tuesday, March 5, 2024
Dialysis, Kidney disease, Patient, Caregiver, DaVita Inc., Fresenius Medical Care, IA Financial Group, Nursing

DENVER, March 5, 2024 /PRNewswire/ -- DaVita Inc (NYSE: DVA), a leading provider of kidney care services, today announced that it has agreed to terms on the expansion of its international operations in Brazil and Colombia, and its entry into Chile and Ecuador. The deal, which is consistent with DaVita's disciplined investment strategy, involves four separate acquisitions from Fresenius Medical Care for a total purchase price of $300M USD. The transaction in Chile closed effective today. The transactions in Ecuador, Colombia and Brazil remain subject to each country's respective anti-trust and regulatory approval processes, which are each expected to be completed at various times during 2024.

Key Points: 
  • The deal, which is consistent with DaVita's disciplined investment strategy, involves four separate acquisitions from Fresenius Medical Care for a total purchase price of $300M USD.
  • The transaction in Chile closed effective today.
  • The transactions in Ecuador, Colombia and Brazil remain subject to each country's respective anti-trust and regulatory approval processes, which are each expected to be completed at various times during 2024.
  • We look forward to building on our existing market expertise and the established quality of these centers through this transition."

PatenSee and Fresenius Medical Care Sign Clinical Collaboration Agreement

Retrieved on: 
Tuesday, February 13, 2024
FDA, Dialysis, Fistula, Fresenius Medical Care, Patient, Medical device

OR YEHUDA, Israel and RAANANA, Israel, Feb. 13, 2024 /PRNewswire/ -- PatenSee, developer of a fistula monitoring system for dialysis patients, has entered into an agreement with Fresenius Medical Care, a leading global provider of dialysis services.

Key Points: 
  • OR YEHUDA, Israel and RAANANA, Israel, Feb. 13, 2024 /PRNewswire/ -- PatenSee, developer of a fistula monitoring system for dialysis patients, has entered into an agreement with Fresenius Medical Care, a leading global provider of dialysis services.
  • Under the agreement, the parties will first collaborate in a joint, multi-center, pilot trial of PatenSee's contactless monitoring system in Fresenius Medical Care's dialysis clinics in Israel.
  • "Timely monitoring and analysis of the fistula status of hemodialysis patients are major clinical unmet needs and PatenSee's contactless, rapid monitoring has the potential to make a significant impact in dialysis patients," said Adi Shaked, Venture Innovation Manager-Israel at Fresenius Medical Care, which is leading the collaboration from the Fresenius Medical Care Ventures team, along with Dr. Alon Antebi, country medical director at Fresenius Medical Care, Israel.
  • We are happy to start this new phase of implementing PatenSee's contactless monitoring technology and even happier to perform this study in collaboration with Fresenius Medical Care with its wealth of experience and clinical expertise," said Shai Policker, chairman of PatenSee.

Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies

Retrieved on: 
Thursday, February 8, 2024
Health care, Dialysis, BAD, Hemofiltration, Kidney, Mortality, FDA, Food, Food and Drug Administration, Fresenius Medical Care, Convection, Diffusion, Engineering, Patient, Water, FME, Blood, Medical device

Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System.

Key Points: 
  • Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System.
  • This will enable Fresenius Medical Care to offer the industry-leading, high-volume hemodiafiltration (Hv-HDF) dialysis therapy – already widely used in Europe – for people living with kidney diseases in the U.S.
  • The 510(k) clearance allows the start of clinical evaluations and user-studies in the U.S., with a planned broad commercial launch of the 5008X Hemodialysis System in 2025.
  • The 5008X Hemodialysis System and companion FX CorAL dialyzer demonstrate the company's global innovation leadership in medical device and membrane engineering technologies.